7月22日 - ** 诊断检测设备制造商OraSure Technologies（OSUR.O）的股价在盘前交易中上涨4.2%，至3.96美元
** 该公司表示，其第二代OraQuick Ebola 2.0全血快速抗原检测试剂（适用于活体患者）已获得美国食品药品监督管理局（FDA）颁发的 (link) 紧急使用授权(（EUA）)
** 该检测试剂也可用于检测死亡时疑似患有埃博拉病的个体的尸检口腔液
** OSUR表示，该检测可检测出目前已知会导致人类患病的全部四种埃博拉病毒：邦迪布吉奥、扎伊尔、苏丹和泰森林
** 刚果已记录超过2,000例埃博拉病例和近1,000例死亡，此次疫情由邦迪布吉奥毒株引起
** 截至上一交易日收盘，该股年内累计涨幅达57%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.